Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Galapagos NV ADR

Healthcare US GLPG

27.27USD
-0.27(0.98%)

Last update at 2026-06-02T13:30:00Z

Day Range

26.9627.69
LowHigh

52 Week Range

24.7337.78
LowHigh

Fundamentals

  • Previous Close 27.54
  • Market Cap1941.58M
  • Volume303524
  • P/E Ratio5.08
  • Dividend Yield-%
  • EBITDA568.17M
  • Revenue TTM1112.25M
  • Revenue Per Share TTM0.84
  • Gross Profit TTM 623.09M
  • Diluted EPS TTM5.69

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 300.87M -3.08500M 5.62M -215.14700M -122.99900M
Minority interest - - - - -
Net income 320.90M 74.08M 211.70M -217.99100M -125.42200M
Selling general administrative 110.57M 94.07M 92.48M 185.50M 97.26M
Selling and marketing expenses 1.39M 2.81M 1.78M 54.03M 69.96M
Gross profit 623.10M 240.79M 239.72M 493.20M 483.22M
Reconciled depreciation 55.88M 45.50M 43.64M 65.57M 34.64M
Ebit 523.20M -2.17400M 7.39M -267.52000M -165.59700M
Ebitda 556.98M 43.33M 51.04M -194.08800M -138.00300M
Depreciation and amortization 33.78M 45.50M 43.64M 73.43M 27.59M
Non operating income net other - - - - -
Operating income 501.39M -188.33800M -88.26300M -267.52000M -165.59700M
Other operating expenses 817.10M 463.99M 327.99M 772.80M 650.44M
Interest expense 1.61M 0.91M 1.65M 6.97M 11.66M
Tax provision -18.62100M -1.80300M 13.12M 2.84M 2.42M
Interest income 46.34M 89.77M 63.56M 18.11M 2.87M
Net interest income 45.19M 89.46M 54.65M 0.90M -18.69900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -18.62100M -1.80300M 9.61M 2.84M 2.42M
Total revenue 1112.20M 275.65M 239.72M 505.28M 484.85M
Total operating expenses 328.00M 429.12M 327.99M 760.72M 648.81M
Cost of revenue 489.10M 34.86M 35.99M 12.08M 1.63M
Total other income expense net -200.52000M 185.25M 93.89M 52.37M 42.60M
Discontinued operations - - - - 22.19M
Net income from continuing ops 319.49M -1.28200M -153.06900M -217.99100M -125.42200M
Net income applicable to common shares - - - -217.99100M -103.23100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3405.07M 4135.72M 4357.40M 4734.35M 5193.16M
Intangible assets 0.85M 164.86M 127.91M 146.35M 60.10M
Earning assets - - - - -
Other current assets 28.17M 123.21M 22.82M 0.00200M -0.00100M
Total liab 170.58M 1238.78M 1561.83M 2208.32M 2549.80M
Total stockholder equity 3234.49M 2896.94M 2795.57M 2526.03M 2643.36M
Deferred long term liab - - - - 11.80M
Other current liab 46.47M 233.57M 0.60M 16.40M 5.10M
Common stock 293.81M 293.94M 293.94M 293.60M 292.07M
Capital stock 293.94M 293.94M 293.94M 293.60M 292.07M
Retained earnings 210.49M -134.30600M -228.27400M -496.68900M -367.20500M
Other liab - - - 1671.10M 1963.67M
Good will 0.00000M 70.01M 69.56M 69.81M -
Other assets - - 0.00000M - 145.49M
Cash 87.83M 64.24M 71.80M 508.12M 2233.37M
Cash and equivalents - - - - -
Total current liabilities 152.80M 335.08M 396.18M 522.54M 566.47M
Current deferred revenue - - 256.27M 365.63M 419.87M
Net debt -80.91560M -52.51700M -62.20700M -486.21600M -2206.50900M
Short term debt 1.73M 3.48M 4.65M 7.21M 7.20M
Short long term debt - - - - -
Short long term debt total 6.92M 11.72M 9.60M 21.90M 26.86M
Other stockholder equity 2727.20M 2736.99M 2736.99M 2735.56M 2730.39M
Property plant equipment - - - 154.25M 137.51M
Total current assets 3078.15M 3339.45M 3846.96M 4236.85M 4861.85M
Long term investments 46.81M 253.12M 13.57M 0.00000M 0.00000M
Net tangible assets - - - - 2595.05M
Short term investments 2908.94M 3053.33M 3612.70M 3585.95M 2469.81M
Net receivables 53.20M 47.48M 65.66M 77.34M 128.60M
Long term debt - - - - -
Inventory 22.49M 51.19M 73.98M 52.92M 20.57M
Accounts payable 104.60M 97.78M 134.65M 133.30M 134.30M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.00M 0.31M -7.09100M -6.44600M -11.89900M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 104.95M 183.90M 25.17M 125.72M 2.47M
Deferred long term asset charges - - - - -
Non current assets total 326.92M 796.27M 510.44M 497.50M 331.31M
Capital lease obligations 6.92M 11.72M 9.60M 21.90M 26.86M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 242.33M 220.60M 12.89M -1245.51400M 570.41M
Change to liabilities - - - -383.61800M -453.72000M
Total cashflows from investing activities 219.35M 220.60M 71.19M -1245.51400M 541.24M
Net borrowings -3.27300M -4.92400M -6.77100M -8.18200M -7.19000M
Total cash from financing activities -3.14382M -4.92400M -5.00100M -1.48700M -3.87600M
Change to operating activities - - - - -35.35400M
Net income 320.90M 74.08M 211.70M -217.99100M -103.23100M
Change in cash -5.06166M -102.57100M -341.30700M -1725.25200M 90.30M
Begin period cash flow 92.89M 166.81M 508.12M 2233.37M 2143.07M
End period cash flow 87.83M 64.24M 166.81M 508.12M 2233.37M
Total cash from operating activities -189.23262M -320.02600M -405.97000M -500.54400M -503.82700M
Issuance of capital stock - - - - 0.00000M
Depreciation 55.88M 35.40M 43.64M 65.57M 34.64M
Other cashflows from investing activities 219.35M 237.32M 16.62M -7.00400M 0.01M
Dividends paid - - - - -
Change to inventory 28.85M 23.04M -24.07600M -34.58800M -21.16800M
Change to account receivables - -31.05500M -39.11400M - 79.86M
Sale purchase of stock - - - - -
Other cashflows from financing activities -3.14382M - 1.77M 6.70M 3.31M
Change to netincome - - - - 8.48M
Capital expenditures 13.16M 82.11M 19.27M 36.95M 57.88M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -885.67550M -65.04300M -692.43500M -351.30500M -430.38200M
Stock based compensation 24.00M 19.89M 56.72M 88.51M 70.73M
Other non cash items 375.54M -362.76000M -37.28100M -88.16400M -7.68500M
Free cash flow -202.39577M -402.13600M -425.24300M -537.49100M -561.70600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GLPG
Galapagos NV ADR		 -0.27 0.98% 27.27 5.08 303.03 1.75 0.51 1.18 -31.4982
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Galapagos NV ADR

Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800

Key Executives

Name Title Year Born
Marieke Vermeersch Head of Corp. Communication NA
Mr. Bart Filius M.B.A., MBA Pres, COO & Member of Management Board 1970
Dr. Andre Hoekema Ph.D. Chief Bus. Officer & Member of Management Board 1957
Dr. Walid Abi-Saab Chief Medical Officer & Member of Management Board 1965
Mr. Michele Manto M.B.A. Chief Commercial Officer & Member of Management Board NA
Dr. Paulus A. Stoffels M.D., Ph.D. CEO, Chairman & Member of Management Board 1962
Ms. Elizabeth Goodwin VP of Investor Relations NA
Ms. Sofie Van Gijsel Head of Investor Relations NA
John Montana Managing Director of Argenta NA
Ms. Chantal Tasset Head of Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.